Understanding how immune cells affect cancer treatment in neuroblastoma
Official title: Immunoregulatory Mechanisms of BiTE Efficacy in the Cold Neuroblastoma TME
Funded at Seattle Children's Hospital · NIH-11074984 · Data updated 2026-11-12
This study is looking at how certain immune cells called regulatory T cells affect the success of a new cancer treatment for neuroblastoma in kids, aiming to find ways to make the treatment work better and help prevent the cancer from coming back.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $195,700 |
| NIH project number | 3U01CA281848-02S1 |
| Project ID | NIH-11074984 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and adults diagnosed with neuroblastoma or acute B-lymphocytic leukemia who are undergoing or considering bispecific T cell engager therapy.
✕Less likely to help
Patients with other types of cancer or those not eligible for bispecific T cell engager therapy may not benefit from this research.
What this research studies
This research investigates the role of regulatory T cells in the effectiveness of bispecific T cell engagers (BTEs) for treating neuroblastoma, a type of cancer that primarily affects children. The study aims to understand how these immune cells influence the response of other T cells during BTE therapy, which connects cancer cells to the body's immune system to enhance cancer cell death. By exploring the mechanisms behind T cell exhaustion and the tumor microenvironment, the research seeks to improve treatment outcomes and long-term protection against cancer relapse.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for neuroblastoma, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promising results with bispecific T cell engagers in treating various cancers, indicating a potential for success in this novel application.
Where this research is happening
-
Seattle Children's Hospital
Seattle, United States Active
Researchers
- Principal investigator: Olson, James M — Seattle Children's Hospital
- Study coordinator: Olson, James M
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.